An epigenetic component of hematopoietic stem cell aging amenable to reprogramming into a young state.

Wahlestedt, Martin; Norddahl, Gudmundur; Sten, Gerd; Ugale, Amol; Micha Frisk, Mary-Ann; Mattsson, Ragnar; Deierborg, Tomas; Sigvardsson, Mikael; Bryder, David

Published in:
Blood

DOI:
10.1182/blood-2012-11-469080

2013

Link to publication

Citation for published version (APA):

Total number of authors:
9

General rights
Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: https://creativecommons.org/licenses/

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
An Epigenetic Component of Hematopoietic Stem Cell Aging
Amenable to Reprogramming Into a Young State

Martin Wahlestedt¹, Gudmundur L Norddahl¹, Gerd Sten¹, Amol Ugale¹, Mary-Ann Micha Frisk², Ragnar Mattsson², Tomas Deierborg³, Mikael Sigvardsson⁴ and David Bryder¹.

¹ Lund University, Medical Faculty, Institution for Experimental Medical Science, Immunology Section, Tornavägen 10, BMC D14, 221 84, Lund, Sweden
² Lund University, Medical Faculty, Institution for Experimental Medical Science, Transgenic Core Facility, Tornavägen 10, BMC C13, 221 84, Lund, Sweden
³ Lund University, Medical Faculty, Institution for Experimental Medical Science, Neuronal Survival Unit, Tornavägen 10, BMC B11, 221 84, Lund, Sweden
⁴ Linköping University, Institution of Clinical and Experimental Medicine, Sandbäcksgatan 7, 581 83, Linköping, Sweden

Running title: Epigenetic Reversal of HSC aging
Text word count: 4000, Abstract word count: 172
Number of figures and tables: 4
Number of references: 34
Corresponding author: David.Bryder@med.lu.se, Phone number: +46-46-2223951, Fax number +46-46-222 42 18
KEY POINTS

1) Hematopoietic stem cell aging associate with stable transcriptional alterations that persist through transplantation.

2) Somatic cell reprogramming of aged hematopoietic stem and progenitor cells reverses functional defects associated with hematopoietic aging.
ABSTRACT

Aging of hematopoietic stem cells (HSCs) leads to several functional changes, including alterations affecting self-renewal and differentiation. While it is well established that many of the age-induced changes are intrinsic to HSCs, less is known about the stability of this state. Here, we entertained the hypothesis that HSC aging is driven by the acquisition of permanent genetic mutations. To examine this issue at a functional level in vivo, we applied induced pluripotent stem (iPS) cell reprogramming of aged hematopoietic progenitors and allowed the resulting aged-derived iPS cells to reform hematopoiesis via blastocyst complementation. Next, we functionally characterized iPS-derived HSCs in primary chimeras and following the transplantation of ‘re-differentiated’ HSCs into new hosts; the gold standard to assess HSC function. Our data demonstrate remarkably similar functional properties of iPS-derived and endogenous blastocyst-derived HSCs, despite the extensive chronological and proliferative age of the former. Our results therefore favor a model in which an underlying, but reversible, epigenetic component is a hallmark of HSC aging rather than being driven by an increased DNA mutation burden.
INTRODUCTION

Many of the pathologies that could benefit from regenerative stem cell based therapies are age-associated\(^1\). An evident example is represented by bone marrow (BM) transplantation, a therapeutic modality that relies on the regenerative capacity of hematopoietic stem cells (HSCs) and where graft age is one of the most significant negative parameters for successful outcome\(^2\). One key mechanism proposed to underlie HSC aging involves the acquisition of permanent genetic changes such as accumulation of DNA damage and/or telomere attrition\(^3\). Yet, while there is a potential role for DNA damage in HSC aging, it is currently unclear if accumulation of DNA damage could explain all or even a part of the distinct transcriptional changes that associate with HSC aging and that ultimately underlie their altered function\(^4\)–\(^7\).

For the purpose of regenerative medicine, alterations in the underlying genomic DNA sequence would be problematic to correct efficiently. By contrast, it might be more conceivable to alter the regulation of the transcriptome of a stem cell population, assuming permanent genomic damage does not underlie and dictate the transcriptional changes. One conceptual example is represented by induced pluripotent stem cells (iPS). iPS cells, created by transcription factor-mediated reprogramming of somatic cells\(^8\), progressively gain particular epigenetic features during the reprogramming process while simultaneously loosing those of the somatic starting cell\(^9\)–\(^10\), to finally reach a relatively stable embryonic stem cell (ES)-like state\(^11\).

Here, to explore the stability and potential reversibility of hematopoietic progenitor cell aging, we generated iPS cells from aged hematopoietic stem and progenitor cells (HSPCs). Next, we used these iPS cells to complement blastocysts. IPS-derived HSCs in chimeric mice were evaluated for several parameters normally altered with age, including their telomere length, reconstitution ability, lineage competence and production of naïve T cells. Our data suggest that a dominant feature of chronological HSC aging is an epigenetic “drift”, which can be reversed by epigenetic reprogramming.
MATERIALS AND METHODS

Mice

All mice were on a C57BL/6 background with the congeneric marker combinations CD45.1, CD45.2 or F1CD45.1 x CD45.2. Animals were housed at animal facilities at Lund University. The Transgenic Core Facility at Lund University performed blastocyst injections. All animal experiments were performed with consent from a local ethical committee.

Retrovirus production

Retroviral vectors (pMXs-Oct3/4-IP, pMXs-Sox2-IP, pMXs-Klf4, pMXs-c-Myc-IP) were acquired from Addgene (Cambridge, MA) and were generously deposited by Shinya Yamanaka. pMX-GFP was obtained from Cell Biolabs (San Diego, CA). Replication incompetent viruses were produced by transfecting the vectors into Plat-E packaging cells (Cell Biolabs, San Diego, CA) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Supernatants were harvested 48h post transfection and titered using the Retro-X qRT-PCR Titration Kit (Clontech, France) and FACS (for pMX-GFP). Viruses used in experiments had titers ranging from $4 \times 10^6$ to $4 \times 10^8$ viral particles/ml.

Hematopoietic stem and progenitor isolation

For iPS generation, mouse bone marrow was depleted of mature cells using a cocktail of biotinylated antibodies (B220, CD4, CD8a, CD11b, Gr-1, Ly6c, Ter119) together with anti-biotin MACS beads (Miltenyi Biotech, Germany), before being further enriched for hematopoietic stem and progenitor cells (HSPCs) by magnetic enrichment of CD117 positive cells (Miltenyi Biotech, Germany). For HSPCs isolation and analysis, lineage-depleted samples were stained with Streptavidin conjugated to QD605 (Invitrogen, Carlsbad, CA) and antibodies recognizing c-Kit, Sca-1, CD48, CD105, CD150, CD45.1 and CD45.2, and sorted on a FACS Aria. Propidium iodide (Invitrogen, Carlsbad, CA) was used to exclude dead cells.
iPS generation from hematopoietic stem and progenitor cells

For prestimulation of primary cells prior to and during transduction, cells were cultured in OptiMEM (Invitrogen, Carlsbad, CA) supplemented with 10% Fetal Calf Serum (FCS), Penicillin/Streptomycin (Invitrogen, Carlsbad, CA), 50 ng/ml SCF, 5 ng/ml IL3 (Peprotech Inc.) and 5 U/ml EPO (Janssen-Cilag, Bersee, Belgium). Both candidate and established iPS cells were cultured under standard ES cell conditions; grown on irradiated mouse embryonic fibroblasts in DMEM (Invitrogen, Carlsbad, CA) containing 15% FCS, Penicillin/Streptomycin (Invitrogen, Carlsbad, CA), 1 mM Sodium pyruvate (Invitrogen, Carlsbad, CA), 0.1 mM β-mercaptoethanol (Invitrogen, Carlsbad, CA), 1x MEM NEAA (Invitrogen, Carlsbad, CA) and 10^3 U/ml LIF (Millipore, Billerica, MA).

To generate iPS lines, 50,000 Lin−c-Kit+ cells were transduced for 2 days using Retronectin (Takara Bio Inc., France) coated plates preincubated with retroviruses and thereafter transferred to ES cell culture conditions. The cells were cultured for 14 days with daily media changes. On day 14, 25 candidate iPS cells were sorted into individual wells of a 96-well plate in ES cell culture conditions based on their negativity for GFP, as iPS induction coincides with efficient silencing of retroviral long terminal repeat regions and CD45, a pan-hematopoietic marker lost during iPS conversion, and by being SSEA-1 and Epcam positive.

Characterization of iPS clones.

iPS lines were assayed for viral vector integration by PCR using one primer specific for each vector’s coding sequence and a common primer directed against the vector backbones. Chimeric mice were genotyped with a similar strategy. PCR reactions were run using Taq polymerase (Takara Bio Inc., France) with initial incubation at 94°C for 2min followed by 35 cycles of 30 sec at 94°C, 30 sec at 60°C and 30 sec at 72°C. In vitro differentiation capacity was investigated by embryoid body formation by cultivating 250 ES or iPS cells in 20ul hanging droplets for 48h in IMDM (Invitrogen, Carlsbad, CA) supplemented with 20% FCS, Penicillin/Streptomycin (Invitrogen, Carlsbad, CA), 1 mM Sodium pyruvate (Invitrogen, Carlsbad, CA), 0.1 mM β-mercaptoethanol (Invitrogen, Carlsbad, CA) and GlutaMAX (Invitrogen, Carlsbad,
CA). Thereafter, cells were pooled and cultured in petri dishes for 12-14 days before analysis. To verify iPS chimerism in adult mice, hippocampal brain sections were used to detect Y chromosome (from iPS cells) by starFISH fluorescence In Situ hybridization protocol (Cambio Ltd, Cambridge, UK).

**Bone marrow transfer and peripheral blood analysis**

For bone marrow reconstitution experiments, young CD45.2 mice were lethally irradiated with 800 rad 3-4h prior to transplantation. Whole bone marrow (2-5 x 10^6 cells) or purified HSCs (200 or 1,500 cells) together with 300,000 unfractionated BM support cells were injected into the tail-vein of recipient animals in a volume of 500 ul. Long-term contribution to the different peripheral blood cell lineages was followed over 16 weeks to assess long-term contribution of the transplanted HSCs. The analysis of the peripheral blood was done as described^{12}. Samples were analyzed on an LSRII (Becton Dickinson, Franklin Lakes, NJ). The competitive ability / transplanted HSC was measured as $X = \frac{(Y*Z)}{(1-Z)} / N$, where X is the competitive ability/transplanted HSC, Y the estimated number of transplanted competitor HSCs (based on the fact that HSCs exist at a frequency of roughly 1/10,000 BM cells), Z the long-term myeloid chimerism and N the actual, or estimated, number of test HSCs transplanted.

**Measurement of T cell excision circles**

T cell receptor excision circles (TRECs) were measured in sorted CD4+/CD8+ splenic T cells by adapting a previously described protocol^{13}. Briefly, the sorted cells were lysed using Proteinase K (Roche, Mannheim, Germany) and assayed for relative TREC content using a SYBR green-based qPCR approach where the cycle threshold value of a primer pair directed against a TREC was normalized against that of the single-copy gene Myt-1. To measure the naïve T cell competence of HSCs in BM transfer experiments, the chimerism of the splenic CD4+/CD8+ compartment was divided by the actual, or estimated, number of transplanted HSCs and multiplied by the relative TREC incidence acquired by qPCR.
Telomere length measurement

To estimate telomere lengths in individual cells, single-cells were isolated using FACS and assayed as previously described\textsuperscript{14-16}.

Affymetrix gene expression analysis

RNA was extracted from 10,000 sorted HSCs (Lin\textsuperscript{-}Sca1\textsuperscript{+}c-Kit\textsuperscript{-}CD48\textsuperscript{-}CD150\textsuperscript{+}) isolated from young or aged mice, or from recipients of young and old bone marrow cells, where they in addition were selected for appropriate CD45 isoform expression, using the RNeasy-micro mRNA purification kit (QIAGEN, Hilden, Germany) as previously described\textsuperscript{12}. Following a two-round amplification protocol, biotin labeling and hybridization to Affymetrix 430.2 gene expression arrays, probe level expression values were extracted using RMA\textsuperscript{17} and analysis performed using the dChip software\textsuperscript{18} following filtering of probes with a lower expression than 100 in either experimental group. To identify differentially expressed genes with age (Figure 1A), genes with a >1.5-fold difference in expression with a confidence interval of >90% were extracted. The microarray data used in this study can be found in the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under accession numbers GSE44923 and GSE27686 (steady-state HSCs), GSE44923 (transplanted HSCs), GSE44923 (YoungBiPS, AgedBiPS and ES cells), GSE6503 (comparative dataset 1), GSE4332 (comparative dataset 2).

qPCR Primers used for SYBR Green mRNA expression analysis

Oct3/4 5\textsuperscript{'-'}-TTCTAGCTCCTTCTGCAGGG -3\textsuperscript{'} (Fw)

5\textsuperscript{'-'}-AGAGGGAAACCTCCTCTGAGC-3\textsuperscript{'} (Rev)

Sox2 5\textsuperscript{'-'}-CTCTGCACATGAAGGAGCAC-3\textsuperscript{'} (Fw)

5\textsuperscript{'-'}-CCGGGAAGCGTGTACTTATC-3\textsuperscript{'} (Rev)

Klf4 5\textsuperscript{'-'}-CAGTCGTAAGGTTTCTCGCC-3\textsuperscript{'} (Fw)

5\textsuperscript{'-'}-GCCACCCACACTTGTGACTA-3\textsuperscript{'} (Rev)

c-Myc 5\textsuperscript{'-'}-ACGGAGTCGTAGTCGAGGTC-3\textsuperscript{'} (Fw)
qPCR Primers used for genomic DNA analysis

Oct3/4 5’-CAGTCCAACCTGAGGTCCAC-3’ (Rev)

Sox2 5’-CCGGGACCATACCATGAA-3’ (Rev)

Klf4 5’-TCCTCACGCAACCGTTAGT-3’ (Rev)

c-Myc 5’-AGGGCTGTACGGAAGTCGTAG-3’ (Rev)

Universal forward primer (viral backbone):
5’ GACGGCATCGCAGCTTGGATACAC-3’

sjTREC 5’-CCAAGCTGACGGCAGGTTT-3’ (Fw)

5’-AGCATGGCAAGCAGCACC-3’ (Rev)

Myt-1 5’-TGCCACCGCTGCTAATGAG -3’ (Fw)

5’-TGCGAACTCCTAAGCCAGCTA-3’ (Rev)

Telomeric repeats:
5’-CGGTGGTTGGGGTTGTTGTTGGTTGGTTGGTT-3’ (Fw)

5’-GGCTTGCTACCTTACCTTACCTTACCTTACCTTACCT-3’ (Rev)

Statistical analysis

Genome-wide gene expression microarray data were analyzed using dChip and GSEA, according to manufacturer’s instructions. For fold-over-odds calculations, we
applied a binomial probability calculation (Poisson distribution approximation). Otherwise, significance values were calculated by Student’s two-tailed t-test.

RESULTS

**Genome-wide expression profiling reveals that an aging hematopoietic stem cell signature is maintained following transplantation**

It is well established that aging imposes several functional shortcomings on HSCs, including pronounced shifts in the types of mature effector cells produced and alterations in self-renewal\textsuperscript{19}. Most existing data argue that these features are autonomous to HSCs since arising phenotypes are visualized when transplanting aged HSCs into young hosts, but not vice versa\textsuperscript{4}. However, one concern with HSC transplantation experiments is that they tend to evaluate HSC function based on retrospective analysis of the produced progeny rather than directly at the level of HSCs. To begin to approach this issue, we transplanted young lethally irradiated mice with stem and progenitor cell-enriched bone marrow cells from young and old donors. 4 months post-transplant, we isolated highly purified lineage negative, Sca-1+, ckit+, CD48- and CD150+ HSCs from these reconstituted animals, and performed genome-wide expression analyses using Affymetrix 430.2 microarrays (“Transplanted HSCs”; 2 biological arrays/condition). We reasoned that this strategy would provide a mean to expose relatively permanent intrinsic gene expression changes, separate from those that associate strictly with cell division, as transplantation enforces vigorous cell cycling of the otherwise quiescent HSCs\textsuperscript{20}. By stringent analysis criteria, these experiments revealed differential expression of 573 probe sets (332 with lower and 241 with higher expression in HSCs derived from aged donors; Table S1). Next, we conducted similar analyses on HSCs from young and aged “steady-state” donors (6 biological replicates for each condition). These experiments revealed 490 probe sets with differential expression in the steady-state situation (Table S1), with the majority being upregulated in aged HSCs (342 probe sets). The gene lists obtained from our two lines of experiments were next intersected to investigate a potential overlap. This revealed a highly significant
correlation for both the “Young-associated” (Figure 1A, odds-ratio: 5.1; p=0.000002) and “Aging-associated” (Figure 1B, odds-ratio: 10.7; p<0.000001) probe sets. In an alternative analysis, we implemented Gene Set Enrichment Analysis (GSEA)\textsuperscript{21}. This independent approach confirmed a highly significant association of the steady-state young and aged HSC profiles to those obtained from young and aged HSCs subjected to transplantation (p<0.001 for both up- and down-regulated genes, Figure S1). A large proportion of these stably differentially expressed genes were also differentially expressed in two independently generated datasets\textsuperscript{4,5} of steady-state young and aged HSCs (Figure S2). These data establish that a core set of transcriptional alterations associate with HSC aging. These, in turn, persist through the multiple rounds of cell divisions that associate with HSC transplantation, and can therefore be regarded as relatively stable.

Establishment of iPS lines from young and aged hematopoietic progenitor cells

To generate iPS cells from hematopoietic progenitor cells, Lin-c-Kit+CD45.1+ HSPCs from young or aged mice were isolated and infected for two consecutive days with retroviruses carrying GFP, Oct3/4, Klf4, c-Myc and Sox2. Thereafter, the cells were transferred to embryonic stem (ES) cell culture conditions. After 4-7 days of culture, we began to observe a vast growth of cells, with the emergence of ES-like colonies from day 14 and onwards. However, the vigorous proliferation of other cells persisted in these cultures, complicating the isolation of emerging iPS colonies. To circumvent this problem, we isolated candidate iPS cells from other cells by FACS using antibodies against EpCAM (CD326)\textsuperscript{22} and SSEA-1 (Figure 2A). This strategy enabled effective removal of other proliferating non-iPS cells (Figure 2B and data not shown). Two iPS lines derived from young HSPCs (Young Blood induced Pluripotent Stem cells; “Young BiPS”) and two lines derived from aged HSPCs (“Aged BiPS”) were selected for further experimentation.

In initial analyses, we confirmed expression of pluripotency factors and induction of Nanog expression by qRT-PCR in the newly generated iPS lines from both young and old mice (Figure 2C). To obtain a wider view of their transcriptional signatures, we performed gene expression analyses of established iPS lines using...
microarrays. For comparative purposes, we also included samples from three
different C57BL/6 ES cell lines. Regardless of young or aged origin, these analyses
revealed highly similar expression patterns of BiPS cells to ES cells (Figure 2D). By
contrast, and as expected, large differences in expression patterns was observed
when comparing iPS or ES cell lines to HSCs (Figure 2D).

To functionally characterize the generated iPS lines, we first investigated
their potential to produce contracting cardiomyocytes in vitro (Movie S1). These
experiments verified their potential to produce cells of an alternative lineage, but of
the same germ layer (mesoderm) as the original somatic donor cells. To further
investigate their lineage potential, we performed a series of blastocyst injections
(Table S2). First, to investigate the potential of BiPS cells to produce a cell lineage
with an alternative (ectodermal) germ layer origin than the starting blood cells, we
investigated neurons in the hippocampus using Y-chromosome detection in brain
sections from a female mouse chimeric with male aged BiPS cells. These analyses
confirmed the presence of robust chimeric contribution to the neural lineage (Figure
2E). Finally, we set up breeding with a male aged BiPS chimeric male with a wild-type
C57BL/6 female, and screened two litters of offspring for germline transmission. Of
17 pups screened, we obtained one mouse with its blood system composing entirely
of F1 CD45.1 x CD45.2 cells (Figure 2F), with CD45.1 representing a marker of BiPS
cells (see below), thereby establishing totipotency of the generated BiPS cells.

Telomere length maintenance of steady state aged and aged BiPS-derived
hematopoietic stem cells

Somatic stem cell pools, including HSCs, are needed for the lifetime of an organism.19
However, increasing numbers of cell divisions could potentially lead to shortening of
telomeres, a mechanism previously proposed to regulate stem cell behavior.23 We
reasoned that this aspect could be particularly relevant in the context of our aged
BiPS cells, given their proliferative history both as a consequence of their
chronological age and because of the substantial proliferation induced in these cells
upon the iPS induction and maintenance. To approach this issue, we examined the
telomere length in individual steady-state young (n = 251) and aged (n =246) HSCs.
These data established that aged HSCs harbored approximately 11% shorter telomeres in comparison to their young counterparts (p<0.0234, Figure 3A), which represents the baseline effect of aging on the telomere length of HSCs.

Although a few previous studies have reported a significant elongation of telomeres in established iPS cell lines compared to the telomere length of the somatic donor cell type, it has remained unclear whether telomere length is appropriately maintained following re-differentiation of iPS cells. Furthermore, it remained a formal possibility that the somatic cell type itself might influence on the telomere length dynamics associated with iPS formation and maintenance. This was relevant to our work, as we used hematopoietic cells, while most previous studies on iPS cells have used fibroblasts as somatic donor cells. When investigating aged BiPS derived HSCs in the primary chimeric setting (which due to cell availability was restricted to the aged BiPS2 clone), we found a striking (2-fold, p<0.0001) elongation of telomeres compared to the blastocyst control HSCs (Figure 3B). Next, we conducted similar experiments on aged BiPS-derived HSCs following transplantation. These experiments demonstrated that aged BiPS maintained their approximately 2-fold elongated telomeres (p<0.0001 for both Aged BiPS1 and Aged BiPS2), despite the exposure of these cells to severe hematopoietic stress/proliferation (Figure 3C). Finally, we investigated the telomere length of HSCs derived from a germline offspring mouse (see Figure 2F). From this mouse, we could observe a significant reduction in telomere length as compared to the telomere length of HSCs from the primary chimera (parent), although telomere length still remained significantly longer in such offspring (approximately 31% longer compared to that of the somatic starting cells, p<0.0001) (Figure 3D). Taken together, these experiments demonstrate that iPS formation from HSPCs associates with elongation of telomeres in a similar manner as previously described for iPS cells with a fibroblast origin.

Reprogramming of aged hematopoietic progenitors into totipotency alleviates the functional alterations that associate with chronological hematopoietic aging

As a last and main aim of our work, we set out to functionally characterize the hematopoietic differentiation capacity of BiPS from aged HSPCs. Despite extensive
research, the exact cues guiding in vitro differentiation of ES/iPS cells into adult-type HSCs have not yet been established. Therefore, we evaluated the hematopoietic differentiation potential of young BiPS and aged BiPS cells in chimeric mice generated via blastocyst injections (Table S2). Because we had a specific interest in the hematopoietic system, we had initially devised our experiments such that we could evaluate the BiPS derived contribution using the congeneric CD45.1 (expressed on BiPS cells) and CD45.2 (blastocyst derived cells) markers. As CD45 is expressed on all nucleated blood cells, this made it possible to detail hematopoiesis derived from young BiPS and aged BiPS in chimeric mice in a direct manner.

As lineage skewing is a dominant feature of HSC aging, we first evaluated the lineage distribution of BiPS derived cells in the primary chimeric mice. These analyses revealed that the hematopoietic lineage distributions of iPS-derived cells, regardless of origin, were remarkably similar to those of the endogenous blastocyst origin (Figure 4A). Another hallmark of HSC aging is a dramatic increase in numbers of phenotypically defined HSCs. We therefore evaluated this aspect in mice chimeric with aged BiPS cells, but failed to observe any differences when comparing to the blastocyst-derived HSCs (Figure 4B). By contrast, and in agreement with previous data, aged steady-state mice displayed dramatically elevated frequencies of HSCs (12.9-fold, p<0.0001; Figure 4B).

Next, we explored the capacity of aged BiPS cells to regenerate a hematopoietic system in a competitive transfer setting. To this end, we transplanted BM mononuclear cells from primary aged BiPS chimeric mice into lethally irradiated CD45.2 recipient hosts (2-5 x 10^6 cells/mouse). 16 weeks after transplantation, we evaluated the aged BiPS and blastocyst derived hematopoiesis in the peripheral blood of these hosts. These experiments revealed the aged BiPS reconstitution to be of similar magnitude and quality when compared to the reconstitution patterns obtained from young HSCs in steady state (Figure 4C and 4D), as well as to the reconstitution pattern observed from the blastocyst control (Figure 4D). This was in sharp contrast to chronologically aged HSCs, which were characterized by a dramatic reduction in repopulation capacity (23.8-fold, p<0.0001) (Figure 4C). Finally, we performed more detailed investigations to explore the intrinsic ability of aged BiPS-
derived HSCs to generate naïve T cells. We were particularly interested in this aspect as this parameter is normally difficult to probe in steady-state aged mice due to the thymic atrophy that accompanies aging. To this end, we estimated the frequencies of T cells containing T-cell receptor excision circles (TRECs), a molecular marker of recent thymic emigrants\textsuperscript{13}, per transplanted HSC. These analyses revealed that steady-state aged HSCs have a strongly reduced T cell potential when compared to their young counterparts (38.4-fold reduction, p=0.005, Figure 4E). By contrast, aged BiPS derived HSCs generated naïve T cells at similar levels as both young HSCs and the endogenous blastocyst control-derived HSCs (Figure 4E).

**ISCUSSION**

Many parameters act together and complicate both the study and generalizations that can be made about the aging of multicellular organisms. These include not only the highly varying onset in both time and degree whereby aging affects different organs and tissues, but also its pleiotropic outcomes. Such considerations aside, one common feature of aging involves what seems as an inevitable loss of overall fitness. At a cellular level, this could result in either the generation of functionally defective cells, a reduced ability in the generation of appropriate cells, or a combination of both scenarios. The recognition that most organs and tissues are maintained by primitive self-renewing stem cells, whose sole function is to provide organisms with appropriate cellular offspring for a lifetime, has in recent years fuelled the emergence of theories of stem cell origins to the aging process\textsuperscript{3,19}. The blood system is particularly amenable to study the autonomous aspects of these processes because of its extensively well-established character and the ability to regenerate an entire blood system from HSCs via transplantation.

An initial striking observation made in these studies was the dramatic elongation of telomeres that associated with the reprogramming process. These telomeres were appropriately maintained during the transition of iPS cells to differentiated progeny, and required germline dilution for substantial shortening, which agree with recent data showing that the combined telomere lengths of the
parents determine telomere lengths of offspring\textsuperscript{30}. However, while telomere extension may be a necessity for the generation of functional iPS cells, the long telomeres of C57BL/6 mice\textsuperscript{14} combined with the fact that chronologically aged HSCs show only modest telomere shortenings, argue perhaps against telomere attrition as the primary driver of murine HSC aging.

We interpret our results on the “young-like” functional capacity of aged-derived BiPS cells to support a view in which reversible epigenetic (and transcriptional) alterations are central for the development and/or maintenance of the phenotypes associated with HSC aging. While a few reports have previously suggested that iPS cells themselves can associate with varying degrees of molecular “resemblance”, or “memory” of its somatic donor origin\textsuperscript{31,32}, we could find little evidence for an epigenetic memory with functional consequences in the BiPS lines studied here. Some data argue that this central question perhaps can be explained from the perspective of an incomplete reprogramming process\textsuperscript{33}. In an alternative interpretation, it might be envisioned that the strategy used in our work could favor selection of a subset of HSPCs unaffected by age and/or DNA damage. While we formally cannot rule out this possibility, we however consider it less likely. This is foremost based on the similarities in efficiencies of iPS formation of young and aged HSPCs (unpublished observations), and the very strong dominance of myeloid-biased HSCs in the aging setting\textsuperscript{4}. It might also be conceivable that aging HSPCs have acquired mutations that by themselves result in altered epigenetic features. An extension of this view would be that initial causative mutations would be compensated for during the iPS process and thus redundant for subsequent redifferentiation. Our experiments did not address this issue directly, but we did find that young BiPS, aged BiPS and ES cells had remarkably similar genome-wide expression profiles and thus showed no evidence of transcriptional compensation.

Previously, sequencing of murine iPS lines revealed a mutational spectra correlating distinctly to that observed in the somatic cell donor cells\textsuperscript{34}. Based on such data, it can be anticipated that if murine HSPC aging do associate with an increase DNA mutation frequency, similar to the aging of human healthy HSPC\textsuperscript{35}, then aged BiPS lines should have significantly more DNA mutations. However, even if this could
be established, its consequence would require extensive sequencing combined with loss and/or gain of function studies; a line of experiments beyond the scope of the work presented here.

We interpret our data to show that the epigenetic reset coinciding with iPS induction has immediate functional benefits for subsequent differentiation. This should be the result of normalized regulation of certain defined loci dysregulated with age, and thus a careful evaluation of the epigenetic properties of aged HSPCs might provide both candidate genes and more general regulators. For instance, the key epigenetic regulator Ezh2 is down regulated in aged HSCs\(^36\). Although we previously found little evidence of epigenetic changes at the \(p16\text{INK4a}\) locus in aged HSCs\(^36\), a well-established Ezh2 target loci in other cells\(^37\), the broad and potent roles of Ezh2 might well underlie other epigenetic alterations governing the HSC aging process\(^38\).

In conclusion, our experiments demonstrate that reprogrammed aged HSPCs have functional differentiation potential similar to those of vastly younger cells. Whether the aging state can be subjected to reversal in a more physiologic or less invasive setting, and not merely in a highly artificial reprogramming scenario, remains a key outstanding question.
ACKNOWLEDGEMENTS

This work was generously supported by project grants to DB from the Swedish Cancer Society, the Swedish Medical Research Council (project grants and consortia grants Hemato-Linné and Stemtherapy), the Swedish Pediatric Leukemia Foundation, Ingabritt och Arne Lundbergs Forskningsstiftelse and an AFA grant for research on regenerative medicine.

AUTHORSHIP

Contribution: D.B. and M.W. planned the study; M.W., G.L.N, G.S. and A.U. performed most experiments; M.M-F. and R.M. undertook the blastocyst injections; T.D. performed the FISH experiments; M.S. helped with microarray hybridizations. M.W., G.L.N and D.B analyzed the data and wrote the manuscript.

Conflict-of-interest disclosure: The authors declare no conflicts of interest.

Correspondence: David Bryder, Immunology section, Institution for Experimental Medical Science, BMC D14, 221 84, Lund, Sweden. Email: David.Bryder@med.lu.se.
REFERENCES

FIGURE LEGENDS

Figure 1. Transcriptional alterations of HSC aging persist through transplantation-mediated stress. (A) Experimental outline. (B) Venn diagrams depicting the number of genes up- or downregulated in HSCs with age, and the overlap of genes that remain differentially regulated as a consequence of HSC aging following transplantation. Numbers in Venn diagrams depict differentially regulated probe sets, with numbers in brackets indicating unique genes. The identities of common genes are shown below each diagram. The analysis was performed on gene expression arrays from two independent experiments totaling six replicate arrays for the young and aged steady-state setting and two replicate arrays for the young and aged transfer setting. Abbreviations: HSC; Hematopoietic Stem Cell.

Figure 2. Generation of iPS cells from bone marrow hematopoietic progenitor cells. (A) FACS strategy to isolate candidate iPS cells from hematopoietic stem and progenitor cells. HSPCs were transduced with retroviruses expressing GFP, Oct3/4, Klf4, c-Myc and Sox2 for two days and subsequently cultured for 14 days in ES cell conditions. On day 14, candidate iPS cells were isolated by FACS based on a GFP-CD45-EpCAM+SSEA-1+ phenotype and cultured in individual wells (25 cells sorted per well) until single iPS colonies emerged. (B) Representative FACS plots of a commercially available C57BL/6 ES cell line (Primogenix B6N1, LEFT), and an established iPS line showing the simultaneous expression of EpCAM and SSEA-1 (RIGHT). (C) Expression of pluripotency factors and induction of Nanog expression in established iPS lines (five independent experiments, 3 replicates / cell line). (D) Correlation plots of the genome-wide expression patterns of Young and Aged BiPS lines to ESCs (one independent experiment, relative expression values were averaged from two replicate arrays per condition). A correlation plot of expression patterns in ESC to HSCs is also shown to highlight the similarity in expression patterns of iPS lines and ESCs. (E) Y chromosome FISH of a cross-section of the hippocampus from a negative control female mouse (TOP) and an AgedBiPS primary chimera (BOTTOM) generated from male AgedBiPS cells injected into a female blastocyst. (F) FACS plots showing the congeneric immunophenotype (CD45.1/CD45.2 system) of the hematopoietic cells used for cell isolation and primary chimera
generation. (BOTTOM RIGHT) Peripheral blood phenotype of a germline contributed AgedBiPS offspring. Abbreviations: FACS; Fluorescence-activated Cell Sorting, HSPCs; Hematopoietic Stem and Progenitor Cells, iPS; induced Pluripotent Stem, ESC; Embryonic stem cell, FISH; Fluorescent In Situ Hybridization.

**Figure 3. Single-cell telomere length analysis of HSCs from various sources.** (A) The relative telomere length was measured by qPCR in single sorted HSCs in two independent experiments from 3 individual young and aged mice, respectively (n=251 and 246 cells in each group). (B) Single cell telomere length measurements of blastocyst- and AgedBiPS2-derived HSCs from an AgedBiPS2 primary chimera (n = 86 and 66 cells in each group respectively). (C) Relative telomere length in blastocyst, AgedBiPS1- and AgedBiPS2-derived HSCs isolated from repopulated recipient mice (two independent isolations, n = 200, 130 and 53 cells respectively). (D) Relative telomere length in (LEFT) blastocyst and AgedBiPS derived HSCs from a germline founder (AgedBiPS2 primary chimera, n = 43 and 41 cells in each group respectively) and (RIGHT) from a germline offspring mouse compared to an age-matched C57BL/6 control (n=84 cells in each group). Error bars indicate mean ± SEM.

**Figure 4. Hematopoiesis derived from iPS lines with an aged hematopoietic progenitor origin display multiple young functional characteristics.** (A) Ratios of the peripheral lineage distribution in individual chimeric animals derived from young and aged BiPS lines. Chimeric ratios are depicted as described previously \(^ {26,27}\) for both blastocyst derived (B) and iPS derived (i) hematopoiesis. Numbers above bars denote individual mice, whose total blood cell chimerism can be found in Table S2. (B) The frequency of HSCs among lineage negative Sca-1 positive c-kit positive bone marrow cells in steady-state young and aged mice (three independent experiments, 6 and 9 mice respectively), and among blastocyst- and AgedBiPS-derived lineage negative Sca-1 positive c-kit positive bone marrow cells in primary chimeras (three independent experiments, totaling 8, 3, and 5 mice respectively). (C) Competitive repopulating ability of young, aged, AgedBiPS1 and AgedBiPS2 HSCs assessed as the ability of each transplanted HSC to repopulate the peripheral myeloid compartment of lethally irradiated young recipients 16 weeks post transfer (three independent experiments, n = 5, 25, 12 and 25 mice per group respectively). (D) In vivo lineage
distribution following transplantation of Young and Aged BiPS HSCs into lethally irradiated young recipients. Analysis was performed as in (A). (E) The ability of transplanted young, aged, blastocyst, AgedBiPS1 and AgedBiPS2 derived HSCs to generate naïve TREC+ T cells in repopulated recipient mice (from two independent experiments, totaling 4, 4, 10, 3 and 7 mice respectively). Bars depict mean ± SEM. Abbreviations: BiPS; Blood induced pluripotent stem, TREC; T cell Receptor Excision Circles.
A

- HSC isolation → Gene expression analysis (Young steady-state)
- Young
  - Bone marrow transplantation → 16 weeks
  - Donor
  - HSC isolation → Gene expression analysis (Young transplanted)

- Aged
  - HSC isolation → Gene expression analysis (Aged steady-state)

B

Fold over odds: 5.1; p=0.000002

- Higher in Young HSCs (in steady-state)
  - 148 (129)
  - 332 (324)

Genes:
- 4933439C20Rik, Arhgap30, Baz1b, Cdca5, Cdt1, Efcb7, Gata1, Hmga2, Kil23, Knk1, LOC433762, LOC63229, Mm.157900.2, Mm.214467.1, Pank1, Plac8, Rad51ap1, Sic22a3, Syk

Fold over odds: 10.7; p<0.000001

- Higher in Aged HSCs (in steady-state)
  - 342 (280)
  - 241 (233)

Genes:
- 1700112E06Rik, 2310001H12Rik, Alcam, Arhgap6, Bmpr1a, C302, C38, Cica1///Cica2, Cica1, Clec1a, Csps, Cyp26b1, Cycil1, D14Erd449e, EGG65317, ENSMUSG00000076577, Epas1, Eya4, Fap, Ffar2, Gda, Gem, Itsn1, Jam2, Lamp2, Ldhd, LOC100044677, LOC664787, Mab212, Milt3, Mm.22185.1, Mm.38121.1, M12, Nrg4, Nup1, Obfc2a, P2ry5, Plc11, Plscr2, Ramp2, Rorb, Sdc4, Sdrp, Selp, Spxb4, Sult1a1, Tbc1d8, Trm4sf1, Trpc1, Wwtr1
SUPPLEMENTARY DATA

The supplemental material accompanying this study consists of a figure showing a GSEA analysis of young and aged steady-state and transplanted HSCs, a figure depicting expression levels of the identified age-associated differentially expressed genes in this study with that of two other datasets, a movie showing contracting cardiomyocytes, an excel spreadsheet with probe sets used in gene expression analyses and a table summarizing generated BiPS chimeric mice.

SUPPLEMENTAL DATA LEGENDS

**Figure S1:** GSEA of genes differentially regulated as a consequence of aging in steady state, and compared to the gene expression patterns of young and aged HSCs subjected to transplantation. The reciprocal analyses are also shown. The analysis was performed on gene expression arrays from two independent experiments totaling six replicate arrays for the young and aged steady-state setting and two replicate arrays for the young and aged transfer setting. Abbreviations: GSEA; Gene Set Enrichment Analysis.

**Figure S2.** Correlation of the genes identified to be differentially expressed in young and aged steady-state and transplanted HSCs to two publicly available datasets. Shown are bar charts depicting the expression levels of the differentially expressed coinciding with both steady-state and transplanted HSCs as a function of age in steady-state Dataset 1\(^1\) and Dataset 2\(^2\). “NA” indicates the absence of probe sets for the analyzed transcripts in Dataset 1. Expression levels are shown relative to the levels in young HSCs of each dataset. Bars depict mean ± SEM.

**Movie S1.** Movie showing contracting cardiomyocytes *in vitro* differentiated from Aged\(^{BIPS}\).

**Table S1.** Excel spreadsheet containing differentially expressed genes upon steady-state aging and after transplantation of young and aged HSCs.
Table S2. Summary of blastocyst injection experiments and blood chimerism levels in chimeric mice generated using Young and Aged BiPS cells. Chimeras #1-25 correspond to #1-25 in Fig. 4A.

REFERENCES

# SUPPLEMENTAL TABLES

## TABLE S2

<table>
<thead>
<tr>
<th>Donor line</th>
<th>Blastocysts injected</th>
<th>Pups (% of implanted)</th>
<th>Chimeras (% of pups)</th>
<th>Blood cell chimerism</th>
</tr>
</thead>
<tbody>
<tr>
<td>Young&lt;sup&gt;BIPS1&lt;/sup&gt;</td>
<td>19</td>
<td>9 (47.4%)</td>
<td>2 (22.2%)</td>
<td>Chimera #1: 13.6% Chimera #2: 15.7%</td>
</tr>
<tr>
<td>Young&lt;sup&gt;BIPS2&lt;/sup&gt;</td>
<td>28</td>
<td>3 (10.7%)</td>
<td>1 (33.3%)</td>
<td>Chimera #3: 14.3%</td>
</tr>
<tr>
<td><strong>Total, Young clones</strong></td>
<td><strong>47</strong></td>
<td><strong>12 (25.5%)</strong></td>
<td><strong>3 (25%)</strong></td>
<td><strong>14.5% (13.6% - 15.7%)</strong></td>
</tr>
<tr>
<td>Aged&lt;sup&gt;BIPS1&lt;/sup&gt;</td>
<td>70</td>
<td>40 (57.1%)</td>
<td>13 (32.5%)</td>
<td>Chimera #4: 13.0% Chimera #5: 3.2% Chimera #6: 48.4% Chimera #7: 4.8% Chimera #8: 14.3% Chimera #9: 35.5% Chimera #10: 14.1% Chimera #11: 9.8% Chimera #12: 23.1% Chimera #13: 13.0% Chimera #14: 6.6% Chimera #15: 29.6% Chimera #16: 5.4%</td>
</tr>
<tr>
<td>Aged&lt;sup&gt;BIPS2&lt;/sup&gt;</td>
<td>46</td>
<td>22 (47.8%)</td>
<td>9 (40.1%)</td>
<td>Chimera #17: 14.2% Chimera #18: 26.1% Chimera #19: 21.6% Chimera #20: 28.3% Chimera #21: 7.0% Chimera #22: 12.7% Chimera #23: 36.0% Chimera #24: 20.7% Chimera #25: 28.4%</td>
</tr>
<tr>
<td><strong>Total, Aged clones</strong></td>
<td><strong>116</strong></td>
<td><strong>62 (53.4%)</strong></td>
<td><strong>22 (33.9%)</strong></td>
<td><strong>18.9% (3.2% - 48.4%)</strong></td>
</tr>
</tbody>
</table>
SUPPLEMENTAL FIGURES

FIGURE S1

GENES UP IN TRANSPPLANTED YOUNG

GENES UP IN STEADY STATE YOUNG

GENES UP IN STEADY STATE AGED

GENES UP IN TRANSPPLANTED AGED

Epigenetic Reversal of HSC aging, Wahlestedt et al.
FIGURE S2